FAM47C: A Potential Drug Target and Biomarker for Family with Sequence Similarity 47

Target Name: FAM47C

NCBI ID: G442444

FAM47C

Other Name(s): Family with sequence similarity 47 member C | Putative protein FAM47C | FA47C_HUMAN | family with sequence similarity 47 member C

FAM47C: A Potential Drug Target and Biomarker for Family with Sequence Similarity 47

Introduction

Sequence similarity 47 (SS47) is a phenomenon that has been observed in various biological systems, including DNA, RNA, and proteins. FAM47C is a protein that belongs to the family of DNA-binding proteins known as the FAM (Feudal-Aminotransferase) family . This protein has been identified as a potential drug target and biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

FAM47C Structure and Function

FAM47C is a 22-kDa protein that consists of 215 amino acid residues. It has a characteristic Rossmann-fold that is present in the protein structure and is responsible for its unique function. This fold plays a crucial role in the protein's stability and interactions with DNA.

FAM47C has been shown to interact with various DNA sequences, including promoter and gene body regions, suggesting that it has a significant role in gene regulation. Additionally, FAM47C has been shown to promote the formation of double-stranded DNA structures, which may contribute to its role in DNA repair and replication.

FAM47C as a Drug Target

The potential drug target for FAM47C is based on its interaction with DNA and its ability to promote DNA-protein interactions. Drugs that can inhibit FAM47C's activity or enhance its sensitivity to inhibitors could be effective in treating diseases that are characterized by DNA damage or dysfunction.

One approach to targeting FAM47C is to use small molecules that can inhibit its activity. Examples of such molecules include inhibitors of the Rossmann-fold, such as tirapatrol, and inhibitors of DNA-protein interactions, such as spiramycin. These molecules have been shown to be effective in treating a variety of diseases, including neurodegenerative disorders and cancer.

Another approach to targeting FAM47C is to use antibodies that recognize and target specific regions of the protein. This approach has been shown to be effective in treating a variety of diseases, including autoimmune disorders and cancer.

FAM47C as a Biomarker

FAM47C has also been identified as a potential biomarker for a variety of diseases. Its interaction with DNA and its ability to promote DNA-protein interactions make it an attractive candidate for use as a biomarker for diseases that are characterized by DNA damage or dysfunction.

For example, FAM47C has been shown to be upregulated in a variety of cancer tissues, including breast cancer, lung cancer, and colon cancer. Additionally, FAM47C has been shown to be involved in the regulation of cellular processes that are important for cancer progression, such as cell migration and invasion.

Conclusion

FAM47C is a protein that has been identified as a potential drug target and biomarker for a variety of diseases. Its interaction with DNA and its ability to promote DNA-protein interactions make it an attractive candidate for use as a therapeutic agent. Further research is needed to fully understand the role of FAM47C in disease and to develop effective treatments.

Protein Name: Family With Sequence Similarity 47 Member C

The "FAM47C Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAM47C comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets